$IRLA News

IRulya Therapeutics to Participate in the Craig-Hallum Biotech Catalyst Conference

Quince Therapeutics Renames as IRulya Therapeutics, Advances Pulmonary Drug Development

Quince Therapeutics Relaunches as IRulya Therapeutics with a Focus on the Clinical Development of LAM-001, Targeting a Key Pathway in Pulmonary Disease

Raymond James Initiates Coverage On Quince Therapeutics with Outperform Rating, Announces Price Target of $72

Quince Therapeutics, Inc. (QNCX) Shareholder/Analyst Call Prepared Remarks Transcript

Quince Therapeutics, Inc. (QNCX) Discusses LAM-001 Clinical Progress in Pulmonary Hypertension and Bronchiolitis Obliterans Syndrome Transcript

This Ares Management Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday

Rodman & Renshaw Initiates Coverage On Quince Therapeutics with Buy Rating, Announces Price Target of $70

Citizens Upgrades Quince Therapeutics to Market Outperform, Announces $77 Price Target

Quince Therapeutics to Host Virtual KOL Event to Discuss the Current Treatment Landscape for PH-ILD and BOS and the Role for LAM-001 as a Potential Therapeutic Option on September 28, 2026

Quince Therapeutics Receives Nasdaq Noncompliance Notice, Gets Time Through Oct. 15 To Regain Compliance

Quince Therapeutics to Participate in September 2026 Investor Conferences

Cantor Fitzgerald Reiterates Overweight on Quince Therapeutics, Maintains $70 Price Target

Quince Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Update

Quince Therapeutics Q2 EPS $(12.31) Beats $(26.32) Estimate

Quince Therapeutics Says Brigette Roberts Conditionally Appointed As CEO; John Militello Conditionally Appointed As CFO

Oppenheimer Initiates Coverage On Quince Therapeutics with Outperform Rating, Announces Price Target of $82

Quince Therapeutics Appoints Recognized Leaders in Pulmonary Medicine to Scientific Advisory Board

Leerink Partners Initiates Coverage On Quince Therapeutics with Outperform Rating, Announces Price Target of $4

Cantor Fitzgerald Initiates Coverage On Quince Therapeutics with Overweight Rating, Announces Price Target of $4